Notably, there were no differences between these two T-BsAbs in terms of accumulation in HER2-negative tumors, demonstrating that relatively high affinity to CD3 could hamper the effective tumor targeting of T-BsAbs due to CD3-mediated trapping in secondary lymphoid tissues by strong binding to T cells localized there [51]. Here, ERBB2 is linked to neoplasm.